Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing RulesKey biosimilar value driver contributes to Sandoz global growth strategy ...

Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson) are now available in the US.

Swiss generics and biosimilars major Sandoz has announced the launch of Pyzchiva (ustekinumab-ttwe) in the USA. From today, ...

Monday said that Pyzchiva (ustekinumab-ttwe) is now commercially available to patients across the U.S. Developed by Samsung Bioepis Co., and commercialized by Sandoz, Pyzchiva has been approved by the ...

Sandoz launches biosimilar Pyzchiva in US, offering new treatment for around 12 million patients: Basel Tuesday, February 25, 2025, 14:00 Hrs [IST] Sandoz, the global leader in ge ...

Pyzchiva is supplied as a 45mg/0.5mL and a 90mg ... infusion. According to Sandoz, the product has extended stability and can be re-refrigerated, unlike the reference medicine.

Developed by Samsung Bioepis Co., Ltd., and commercialized by Sandoz, Pyzchiva® has been approved by the US Food and Drug Administration (FDA) for the treatment of certain chronic inflammatory ...

Key biosimilar value driver contributes to Sandoz global growth strategy and ... arthritis Meeting a variety of patient needs, Pyzchiva® offers full suite of dosing options and extended stability ...